Allos Therapeutics, Inc.

How long is too long when it comes to confirming or refuting clinical benefit of an accelerated approval drug? That question is at the heart of a US Food and Drug Administration advisory committee mee

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Citeline's Biomedtracker. Lotus Licenses Corium’s Alzh

Step Pharma is advancing its lead CTP synthase 1 inhibitor candidate into the clinic this year in the hopes of treating an aggressive lymphoma indication with poor prognosis and limited second-line t

Sanofi ‘s board of directors has proposed the appointments of Melanie Lee and Bernard Charlès as new independent directors. Lee has been chief scientific officer at BTG Plc since 2014. She fo